{"id":"https://openalex.org/W7220858563","doi":"https://doi.org/10.3389/fmed.2026.1998014","title":"Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing after CD19 CAR T-cell therapy","display_name":"Case Report: Durable, well-tolerated complete response to epcoritamab plus pirtobrutinib in Richter transformation relapsing after CD19 CAR T-cell therapy","publication_year":2026,"publication_date":"2026-10-07","ids":{"openalex":"https://openalex.org/W7220858563","doi":"https://doi.org/10.3389/fmed.2026.1998014","pmid":"https://pubmed.ncbi.nlm.nih.gov/42908725","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13683116"},"language":"en","primary_location":{"id":"doi:10.3389/fmed.2026.1998014","doi":"https://doi.org/10.3389/fmed.2026.1998014","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fmed.2026.1998014","pdf_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1998014/pdf","source":{"id":"https://openalex.org/S2597052008","display_name":"Frontiers in Medicine","issn_l":"2296-858X","issn":["2296-858X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1998014/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5107366713","display_name":"Ahmed Salleh Barefah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I185163786","display_name":"King Abdulaziz University","ror":"https://ror.org/02ma4wv74","country_code":"SA","type":"education","lineage":["https://openalex.org/I185163786"]}],"countries":["SA"],"is_corresponding":true,"raw_author_name":"Ahmed Salleh Barefah","raw_affiliation_strings":["Hematology Department, Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University","Hematology Research Unit, King Fahad Medical Research Center, King Abdulaziz University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Department, Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University","institution_ids":["https://openalex.org/I185163786"]},{"raw_affiliation_string":"Hematology Research Unit, King Fahad Medical Research Center, King Abdulaziz University","institution_ids":["https://openalex.org/I185163786"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5107366713"],"corresponding_institution_ids":["https://openalex.org/I185163786"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.73059016,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"13","issue":null,"first_page":"1998014","last_page":"1998014"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9721999764442444,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9721999764442444,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.008799999952316284,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.007000000216066837,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/richter-transformation","display_name":"Richter transformation","score":0.9919999837875366},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9010000228881836},{"id":"https://openalex.org/keywords/cd19-car-t-cell-therapy","display_name":"CD19 CAR T-cell therapy","score":0.8389999866485596},{"id":"https://openalex.org/keywords/epcoritamab","display_name":"epcoritamab","score":0.9390000104904175},{"id":"https://openalex.org/keywords/pirtobrutinib","display_name":"pirtobrutinib","score":0.968999981880188},{"id":"https://openalex.org/keywords/cd3xcd20-bispecific-antibody","display_name":"CD3xCD20 bispecific antibody","score":0.9549999833106995},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9739999771118164},{"id":"https://openalex.org/keywords/relapsed-lymphoma","display_name":"relapsed lymphoma","score":0.6660000085830688},{"id":"https://openalex.org/keywords/osteolytic-bone-disease","display_name":"osteolytic bone disease","score":0.7599999904632568},{"id":"https://openalex.org/keywords/complete-metabolic-response","display_name":"complete metabolic response","score":0.7039999961853027},{"id":"https://openalex.org/keywords/pet-ct-response-assessment","display_name":"PET/CT response assessment","score":0.8270000219345093},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.6480000019073486},{"id":"https://openalex.org/keywords/frail-older-patients","display_name":"frail elderly patients","score":0.7879999876022339},{"id":"https://openalex.org/keywords/chemotherapy-free-regimen","display_name":"chemotherapy-free regimen","score":0.8090000152587891}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.741100013256073},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.520799994468689},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.5030999779701233},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.48989999294281006},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48660001158714294},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.42480000853538513},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.41659998893737793},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.3596999943256378},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3569999933242798},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35600000619888306},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.3499999940395355},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3418999910354614},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.3407999873161316},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.33379998803138733},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.32760000228881836},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.3147999942302704},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.311599999666214},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.299699991941452},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2987000048160553},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2978000044822693},{"id":"https://openalex.org/C185926286","wikidata":"https://www.wikidata.org/wiki/Q1929812","display_name":"Systemic therapy","level":4,"score":0.2939999997615814},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.2743000090122223},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.2700999975204468},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2669000029563904},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.26109999418258667},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.25760000944137573}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fmed.2026.1998014","doi":"https://doi.org/10.3389/fmed.2026.1998014","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fmed.2026.1998014","pdf_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1998014/pdf","source":{"id":"https://openalex.org/S2597052008","display_name":"Frontiers in Medicine","issn_l":"2296-858X","issn":["2296-858X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Medicine","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13683116","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13683116/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13683116/pdf/fmed-13-1998014.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Med (Lausanne)","raw_type":"Text"},{"id":"pmid:42908725","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42908725","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in medicine","raw_type":"Case Reports"},{"id":"pmh:oai:doaj.org/article:015d892f255346b9a8d92ad824724b33","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/015d892f255346b9a8d92ad824724b33","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Medicine, Vol 13 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fmed.2026.1998014","doi":"https://doi.org/10.3389/fmed.2026.1998014","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fmed.2026.1998014","pdf_url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1998014/pdf","source":{"id":"https://openalex.org/S2597052008","display_name":"Frontiers in Medicine","issn_l":"2296-858X","issn":["2296-858X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7220858563.pdf","grobid_xml":"https://content.openalex.org/works/W7220858563.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W2119147717","https://openalex.org/W2159862107","https://openalex.org/W2553979195","https://openalex.org/W2790385276","https://openalex.org/W2799716396","https://openalex.org/W3082855561","https://openalex.org/W3109460058","https://openalex.org/W4377563779","https://openalex.org/W4383197912","https://openalex.org/W4393304844","https://openalex.org/W4396229633","https://openalex.org/W4400763592","https://openalex.org/W4402397977","https://openalex.org/W4402827909","https://openalex.org/W4409487670","https://openalex.org/W4409539766","https://openalex.org/W4417136085","https://openalex.org/W7133237031","https://openalex.org/W7163402788","https://openalex.org/W7166554856","https://openalex.org/W7168838592"],"related_works":["https://openalex.org/W4414243208","https://openalex.org/W4417004873","https://openalex.org/W4391611150","https://openalex.org/W4413540881","https://openalex.org/W4412957745","https://openalex.org/W4417136085","https://openalex.org/W4417004935","https://openalex.org/W4407976815","https://openalex.org/W4408967307","https://openalex.org/W4393304844"],"abstract_inverted_index":{"Richter":[0],"transformation":[1],"(RT)":[2],"that":[3,85,181],"relapses":[4],"after":[5,51,117,156],"CD19-directed":[6],"chimeric":[7],"antigen":[8],"receptor":[9],"(CAR)":[10],"T-cell":[11,176],"therapy":[12,16],"has":[13],"no":[14,59,132,136,139],"established":[15],"and":[17,36,119,138,179],"carries":[18],"a":[19,37,65,71,88,189],"dismal":[20],"prognosis.":[21],"We":[22],"report":[23],"an":[24],"84-year-old":[25],"man":[26],"with":[27,46,63,99,131,168,197],"multiply":[28],"relapsed,":[29],"biopsy-proven":[30],"diffuse":[31],"large":[32],"B-cell":[33],"lymphoma-type":[34],"RT":[35,198],"high-risk":[38],"MYC/BCL2":[39],"double-expressor":[40],"phenotype":[41],"who":[42,199],"developed":[43],"systemic":[44],"relapse,":[45],"extensive":[47],"osteolytic":[48,104],"bone":[49],"disease,":[50],"lisocabtagene":[52],"maraleucel.":[53],"Three":[54],"cycles":[55],"of":[56,101,113,160],"atezolizumab":[57],"produced":[58,77],"objective":[60],"benefit.":[61],"Treatment":[62],"epcoritamab,":[64],"CD3xCD20":[66],"bispecific":[67],"antibody,":[68],"plus":[69,170],"pirtobrutinib,":[70],"non-covalent":[72],"Bruton":[73],"tyrosine":[74],"kinase":[75],"inhibitor,":[76],"complete":[78,89],"nodal":[79],"metabolic":[80,90],"resolution":[81,100],"within":[82],"3":[83],"months":[84,159],"deepened":[86],"to":[87,173],"response":[91,115],"(Deauville":[92],"score":[93],"2)":[94],"by":[95],"10":[96,158],"treatment":[97],"cycles,":[98],"two":[102],"interim":[103],"lesions":[105],"whose":[106],"transient":[107],"nature":[108],"illustrates":[109],"the":[110,141,165,174],"interpretive":[111],"challenges":[112],"PET/CT":[114],"assessment":[116],"cellular":[118],"T-cell-engaging":[120],"therapies.":[121],"The":[122,149],"chemotherapy-free":[123,183],"regimen":[124],"was":[125,144],"well":[126],"tolerated":[127],"at":[128],"age":[129],"84,":[130],"cytokine":[133],"release":[134],"syndrome,":[135],"neurotoxicity,":[137],"cytopenias;":[140],"only":[142],"toxicity":[143],"mild,":[145],"reversible":[146],"dexamethasone-related":[147],"myopathy.":[148],"patient":[150],"remains":[151],"in":[152],"ongoing":[153],"clinical":[154],"remission":[155],"approximately":[157],"therapy.":[161,205],"This":[162],"case":[163],"extends":[164],"reported":[166],"experience":[167],"epcoritamab":[169],"pirtobrutinib":[171],"specifically":[172],"post-CAR":[175],"relapse":[177],"setting":[178],"suggests":[180],"this":[182],"doublet":[184],"may":[185],"warrant":[186],"consideration":[187],"as":[188],"salvage":[190],"strategy":[191],"for":[192,202],"older":[193],"or":[194],"frail":[195],"patients":[196],"are":[200],"unfit":[201],"further":[203],"cytotoxic":[204]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-08T00:00:00"}